EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.

Sinem Başak Tan Öksüz, Güldane Cengiz Seval, Klara Dalva, Selami Koçak Toprak

Mediterranean Journal of Hematology and Infectious Diseases · 28.02.2026 · 18 (1) · e2026028

DOI: 10.4084/mjhid.2026.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 28.02.2026. Verfasst von Sinem Başak Tan Öksüz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Türkiye. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (AHSCT) in acute leukemia. Early molecular detection is critical for timely intervention. Measurable residual disease (MRD) and donor chimerism are routinely used for post-transplant monitoring, yet their comparative predictive value is uncertain.

Aims

To compare the prognostic utility of MRD and donor chimerism in predicting relapse after AHSCT in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Methods

This retrospective cohort included 264 adults (186 AML, 78 ALL) who underwent AHSCT. MRD was assessed by multiparametric flow cytometry on day 28 and at months 3 and 12, and chimerism by short tandem repeat PCR. Cox regression identified independent relapse predictors.

Results

Ninety-five patients relapsed (68 AML, 27 ALL). In AML, MRD positivity at month 3 (HR = 3.69, p < 0.001) and mixed chimerism (MC) (HR = 2.47, p = 0.029) were independent relapse predictors and correlated with inferior survival. MRD predicted relapse in 60% of AML cases versus 38% for MC. In ALL, only T-cell lineage independently predicted relapse (HR = 3.94, p = 0.016).

Conclusion

Post-transplant MRD monitoring at month 3 is a stronger independent predictor of relapse than chimerism in AML, while in ALL, the small cohort size limits statistical power; thus, the roles of MRD and chimerism should be interpreted cautiously.

Schlagwörter

Stichwörter der Autor:innen

Acute leukemiasAllogeneic hematopoietic stem cell transplantationChimerismMeasurable residual diseaseMultiparametric flow cytometry

Autor:innen und Institutionen

  • Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Türkiye.
  • Department of Hematology, Ankara University Faculty of Medicine, Ankara, Türkiye.

Zitieren

APA

Öksüz, S. B. T., Seval, G. C., Dalva, K., & Toprak, S. K. (2026). POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026028. https://doi.org/10.4084/mjhid.2026.028

Vancouver

Öksüz SBT, Seval GC, Dalva K, Toprak SK. POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026028. doi:10.4084/mjhid.2026.028

BibTeX
@article{ksz2026,
  author = {Öksüz, Sinem Başak Tan and Seval, Güldane Cengiz and Dalva, Klara and Toprak, Selami Koçak},
  title = {POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM},
  journal = {Mediterranean Journal of Hematology and Infectious Diseases},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {e2026028},
  doi = {10.4084/mjhid.2026.028}
}
Kostenlos starten →